AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Lausanne, Switzerland, March 25, 2025– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.

Industry Symposium: Unlocking active immunotherapy for tailored prevention strategies in neurodegenerative diseasesSession Date/Time: Wednesday, April 2, 2025, at 8:40 – 10:40 am CETLocation: Hall A

Opening and Closing Remarks:Andrea Pfeifer, Ph.D., CEO of AC Immune

Perspectives of disease-modification in Parkinson’s diseasePresenter: Werner Poewe, M.D. (Medical University of Innsbruck)Time: 8:50 – 9:10 am CET

Targeting alpha-synuclein in early Parkinson’s disease: ACI-7104.056 in the Phase 2 trial VacSYnPresenter: Günther Staffler, Ph.D. (AC Immune)Time: 9:10 – 9:25 am CET

Precision Prevention for Alzheimer’s diseasePresenter: Philip Scheltens, M.D., Ph.D. (EQT Life Sciences, Amsterdam University Medical Center) Time: 9:25 – 9:50 am CET

The first active immunotherapy for AD prevention: ACI-35.030/JNJ2056 in the Phase 2b Retain studyPresenter: Lennert Steukers, Ph.D. (Johnson & Johnson Innovative Medicine)Time: 9:50 – 10:05 am CET

Anti-Abeta active immunotherapy in early AD and DSAD: ACI-24.060 in the Phase 1b/2 ABATE studyPresenter: Anke Post, M.D., Ph.D. (AC Immune)Time: 10:05 – 10:20 am CET

The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune’s website after the event.Oral PresentationsMorphomer® small molecules targeting Tau for the treatment of Alzheimer’s diseasePresenter: Nicolas Preitner, Ph.D. (AC Immune)Session:Translational Drug Development and Experimental ModelsLocation: Hall CDate/Time: Saturday, April 5, 2025, at 16:40 – 16:55 pm CET

Development of Morphomer-antibody drug conjugates – a new class of drugs for neurodegenerative diseasesVirtual On-Demand Oral Presentation -Virtual OO - 186Presenter: Nampally Sreenivasachary, Ph.D. (AC Immune)

Discovery and optimization of therapeutic small molecules targeting alpha-synuclein aggregationVirtual On-Demand Oral Presentation -Virtual OO - 187Presenter: Elpida Tsika, Ph.D. (AC Immune)Poster PresentationsDefining optimal thresholds for time-to-event endpoints for Parkinson’s disease clinical trialsPoster on Board -SHIFT 02-066Presenter: Nicolas Sanchez (AC Immune)Presentations and posters by our collaboration partnersAntibodies generated by JNJ-64042056, an active anti-pTau immunotherapy, in clinical trial ACI-35-1802 can block Tau seeding in neuronsPresenter: Clara Theunis, Ph.D. (Johnson & Johnson Innovative Medicine)Session:Abeta & Tau ImmunotherapiesLocation: Hall EDate/Time: Saturday, April 5, 2025, at 12:40 – 12:55 am CET

Immunization with JNJ-64042056 generates antibodies in non-human primates that inhibit Tau aggregation in a neuronal Tau seeding modelPoster on Board -SHIFT 02-636Presenter: Bruno Vasconcelos, Ph.D. (Johnson & Johnson Innovative Medicine)

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.